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ABSTRACT | Purpose: To assess the compliance, efficacy, 
and safety of the long-term use of topical tacrolimus for the 
clinical management of vernal keratoconjunctivitis. Methods: 
The medical records of patients with vernal keratoconjunctivitis 
undergoing long-term treatment with 0.03% topical tacrolimus 
were retrospectively reviewed. The duration of tacrolimus use 
and the causes for drug discontinuation were used to assess 
treatment compliance. To assess drug efficacy, the need for and the 
number of times that topical corticosteroids were used to control 
symptoms were registered. Side effects related to tacrolimus use 
were monitored to determine drug safety. Results: The study 
cohort consisted of 21 patients who met the eligibility criteria. 
The mean duration of tacrolimus use was 41.3 ± 18.5 months. 
Fourteen patients (66.7%) continuously used tacrolimus, and three 
(14.3%) discontinued treatment following complete remission. 
Four patients (19%) did not use tacrolimus as prescribed or 
interrupted tacrolimus use on their own: two (9.5%) because 
of discomfort upon application and two (9.5%) because of the 
lack of improvement. Ten patients (47.6%) maintained disease 
control without the use of corticosteroids, whereas 11 (52.4%) 
required an average of 2.70 ± 1.35 corticosteroid cycles to 
control symptoms. The only reported side effect was discomfort 
upon application. Conclusions: Despite the small sample size 
and study design limitations, these results support the long-term 
use of topical tacrolimus as an effective and safe option for the 
treatment of vernal keratoconjunctivitis, with good compliance 
of patients to the treatment.
Keywords: Cornea, Vernal keratoconjunctivitis, Tacrolimus, Allergic 
conjunctivitis, Antiallergic drugs
RESUMO | Objetivo: Avaliar a aderência, a eficácia e segurança 
do uso prolongado de tacrolimus tópico no controle clínico da 
ceratoconjuntivite vernal. Métodos: Um estudo retrospectivo 
foi desenvolvido através da análise de prontuários de pacientes 
com ceratoconjuntivite vernal em tratamento prolongado com 
tacrolimus tópico 0,03%. A duração do tempo de uso do ta-
crolimus e as causas de descontinuação da medicação foram 
usadas para avaliar a adesão ao tratamento. Para avaliar a 
eficácia da droga, a necessidade e o número de vezes em que 
corticoides tópicos foram utilizados para controlar os sintomas 
foram registrados. Os efeitos colaterais relacionados ao uso do 
tacrolimus foram monitorados para determinar a segurança 
da droga. Resultados: Vinte e um pacientes preencheram os 
critérios de eleição e foram incluídos no estudo. A duração 
média do uso de tacrolimus foi de 41,3 ± 18,5 meses. Quatorze 
pacientes (66,7%) usaram continuamente o tacrolimus e 3 (14,3%) 
descontinuaram o tratamento após a remissão completa. Quatro 
pacientes (19%) não usaram o tacrolimus conforme prescrito 
ou interromperam o uso da droga isoladamente: 2 (9,5%) por 
desconforto na aplicação e 2 (9,5%) pela falta de melhora. Dez 
pacientes (47,6%) mantiveram a doença sob controle sem o uso 
de corticoides, enquanto 11 (52,4%) necessitaram em média 
2,70 ± 1,35 ciclos corticoides para controle dos sintomas. O 
único efeito adverso relatado foi desconforto na aplicação. 
Con clusões: Apesar do pequeno tamanho da amostra e das 
limitações do desenho do estudo, esses resultados suportam 
o uso prolongado do tacrolimus tópico como opção eficaz e 
segura para o tratamento da ceratoconjuntivite vernal, com 
boa adesão dos pacientes ao tratamento.
Descritores: Ceratoconjuntivite vernal, ceratoconjuntivite prima-
veril, tacrolimus, conjuntivite alérgica, antialérgicos
INTRODUCTION
Vernal keratoconjunctivitis (VKC) is an allergic di-
sease that affects children and young adults and is one 
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of the most severe forms of atopic ocular disease. Clas-
sically, the incidence of VKC peaks in the summer and 
spring. However, 60% of cases can become chronic with 
persistent symptoms(1). The course of VKC is self-limited 
with initial symptoms appearing at the age of approxi-
mately 7 years and peaks between the ages of 11 and 13 
years. VKC is more prevalent in boys until the age of 14 
years, but this tendency decreases at the age of 20 years, 
when the disease prevalence is equal between the sexes.
Clinical signs of VKC include conjunctival hyperemia 
and a significant papillary reaction of the tarsal, parti-
cularly of the upper tarsal. VKC may cause different 
lesions, from punctate epithelial keratopathy to ulcera-
tions, with corneal neovascularization and conjunctival 
fibrosis at later stages(2-4). VKC is mainly characterized 
by intense itching, but patients also frequently complain 
of lacrimation, foreign body sensation and photopho-
bia(3,5). There are three different clinical forms of VKC: 
the palpebral form, which is characterized by giant 
papillae in the upper tarsal; the limbal form, with gela-
tinous nodules composed of eosinophilic infiltrates and 
degenerated epithelial cells (Horner-Tantras dots); and 
a mixed form(1).
Among the most frequent complications of VKC, ke-
ratoconus stands out because of its high incidence and 
greater severity of ectasia; therefore, good management 
of symptoms is imperative during the active phase of 
the disease. A large number of studies have correlated 
the act of rubbing the eyes with the advancement of 
keratoconus(6-11). Although the pathophysiology of this 
mechanism remains unknown, some studies have sug-
gested that chronic mechanical trauma to the corneal 
epithelium can result in the prolonged release of small 
quantities of enzymes that lead to the disruption of colla-
gen fibers(10).
The treatment of VKC involves, in addition to envi-
ronmental control measures, the use of anti-histamines 
(AIs) and topical mast cell stabilizers (MCSs), which are 
usually sufficient to control symptoms in mild cases(12,13). 
However, a high number of patients are refractory to 
allergy therapy and require treatment with topical ste-
roids. Side effects related to long-term steroid use, such 
as increased intraocular pressure, cataract development, 
and increased susceptibility to infections, limit its use to 
short cycles of topical steroids(3,14).
The development of new immunomodulatory drugs 
with mechanisms of action similar to that of steroids, but 
without its side effects, appears as a treatment option for 
these patients. Tacrolimus (TCL), a macrolide immuno-
suppressant derived from Streptomyces tsukubaensis, is 
an alternative to steroid therapy for allergic diseases of 
the ocular surface. TCL acts on CD4+ T lymphocytes 
preventing IL-2 production by inhibiting calcineurin, 
thereby blocking the inflammatory cascade and the 
recruitment of eosinophils, an important step in the 
pathogenesis of the disease. In addition, TCL also acts 
on mast cells as a membrane stabilizer by inhibiting the 
release of histamines and the production of prosta-
glandins(15-17).
Several studies have demonstrated the effective control 
of symptoms and signs in VKC patients who use to pical 
TCL, avoiding the long-term use of steroids and the 
subsequent side effects(18-21). However, few studies have 
monitored long-term TCL therapy in VKC patients.
The objective of this study was to assess the compliance, 
efficacy, and safety of long-term therapy with topical TCL 
for the clinical management of VKC.
METHODS
In this non-randomized study, the medical records of 
VKC patients being followed up at the External Diseases 
Outpatient Clinic of the Clinics Hospital of the State Uni-
versity of Campinas from February 2011 to September 2017 
were retrospectively reviewed. The diagnosis of VKC 
was based on a clinical history of recurrent/persistent 
conjunctivitis associated with intense ocular itching and 
a marked papillary reaction with giant papillae in the 
upper tarsus and/or Horner-Tantras dots in both eyes. 
The therapeutic scheme followed a standard flowchart, 
as depicted in figure 1.
The patients selected to participate in this study had 
already used or were currently using topical TCL for the 
management of VKC. A dermatologic formulation of 0.03% 
TCL ointment (Protopic®; Astellas Pharma Tech Co., Ltd., 
Toyama, Japan) was prescribed to patients for applica-
tion on the conjunctival fornix every 12 h. Proper use 
of this off-label drug was explained to the patient and/
or person responsible for the treatment, who also signed 
an informed consent form after agreement to par ticipate 
in this study.
VKC was considered to be under control if the pa-
tient reported significant improvement of the following 
symptoms without interference with daily activities: 
reduction of itching until there was no urge to rub the 
eyes and reductions in the incidences of lacrimation, 
foreign body sensation, and photophobia.
The duration of TCL use was registered, and com-
pliance to treatment was defined as adherence to the 
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medical prescription. Those patients who discontinued 
the medication or did not use TCL as prescribed were 
considered non-compliant. The reasons for non-com-
pliance were registered.
For cases in which symptoms were not under control 
(active disease), short cycles of steroids with tapering 
doses were prescribed (Figure 1). The need to add a to-
pical steroid to the treatment regimen and the number of 
steroid cycles prescribed were used as inversely propor-
tional parameters to assess treatment efficacy. The me-
dical decision to use high- or low-penetration steroids 
was made on a case-by-case basis.
To determine drug safety, the incidence of side effects 
related to TCL use was assessed. AI and MCS drugs were 
used as necessary; however, the patients were advised 
against more than two applications per day.
RESULTS
Of 42 patients being followed up for VKC in the out pa-
tient clinic, 24 had used or were using topical TCL until 
the time of data collection. Three patients discontinued 
TCL use because of a lack of economic resources and 
were excluded from the study. Of the 21 patients assessed, 
8 were female and 13 were male, with a mean age of 12 
(range, 7-23) years. Patients who did not use TCL (n=18) 
managed VKC with AI and MCS drugs.
The mean duration of TCL use among the study parti-
cipants was 41.3 ± 18.5 (range, 6-45) months. Of these 
patients, 14 (66.7%) with VKC used TCL continuously 
and 3 (14.3%) discontinued TCL use following complete 
remission (patients used TCL for 14, 30 and 40 mon-
ths). The mean duration of TCL use for these 17 (81%) 
patients was 45 ± 16.9 months. The remaining four 
(19%) patients did not use TCL according to the medical 
prescription or discontinued its use on their own: two 
(9.5%) because of discomfort upon TCL application and 
two (9.5%) because of no perceived improvement. The 
mean duration of TCL use for these four patients was 
25 ± 17.6 months.
Ten (47.6%) patients achieved disease control without 
the use of steroids. Of these, seven patients used TCL 
continuously and three discontinued use following the 
complete remission of symptoms. Steroids were necessa-
ry to manage disease in 11 (52.4%) patients, with a mean 
of 2.70 ± 1.35 (range, 1-5) cycles/patient as described in 
figure 1. Of these, seven patients used TCL continuously 
(mean, 2.5 cycles) and four used TCL irregularly or dis-
continued TCL use on their own (mean, 3.5 cycles).
Two patients discontinued TCL use because of dis-
comfort upon application (i.e., transient burning sen-
sation, photophobia, and tearing). No other side effects 
were reported by the patients during the study period 
(Figure 2).
DISCUSSION
In this study, compliance to the topical TCL regimen 
was high, as 17 (80.9%) of 21 patients used TCL as pres-
cribed. The duration of TCL use was higher in this group 
of patients as compared with those who discontinued 
treatment without a medical decision. The efficacy of 
TCL as an alternative to steroid treatment for VKC was 
also demonstrated by fewer steroid cycles among pa-
tients who regularly used TCL. The hypothesis that TCL 
has a beneficial effect on VKC management is supported 
by the fact that all patients who did not add steroids to 
their treatment regimen used TCL continuously during 
the study period.
The optimal concentration of TCL remains under dis-
cussion, as doses described in the literature range from 
0.01% to 1%. Because no ophthalmologic formulation Figure 1. VKC treatment protocol.
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Figure 2. Participant flowchart.
is commercially available, a dermatological ointment was 
chosen for use on the basis of descriptions in the literature 
of good efficacy and tolerability without significant side 
effects(18,20,22,23). We decided to use a lower concentration 
(0.03%) because, in addition to the fact that such a dose 
has resulted in a good therapeutic response in other stu-
dies, the formulation of TCL for VKC is not commercially 
available and the side effects are unknown.
In a study involving atopic keratoconjunctivitis patients 
who used 0.1% topical TCL continuously for 49 months, 
Al-Amri et al. observed that all patients achieved disease 
management without the use of CTCs or other drugs(24). 
Labcharoenwongs et al. observed a significant impro-
vement of symptoms with the use of 0.1% topical TCL 
without the need to add steroids or other drugs to control 
the disease(25). In a case report, Zribi et al. added 0.03% 
TCL to the treatment regimens of four patients with atopic 
keratoconjunctivitis and discontinued steroid use(26).
The absence of serious side effects during this study 
highlights the safety of prolonged use of TCL. Discomfort 
upon application, with complaints of transient burning, 
photophobia, and lacrimation, was the most frequent 
side effect and was also the reason for treatment discon-
tinuation in two patients. Although there are descrip-
tions in the literature, no case of herpetic keratitis or other 
ocular surface infectious disease associated with topical 
TCL was reported(26,27).
Even though three patients achieved complete re-
mission of symptoms after 14, 30 and 40 months of TCL 
treatment and were thus able to discontinue TCL thera-
py, two others discontinued TCL treatment because of 
the absence of improvement even following long-term 
TCL treatment (10 and 36 months). Even if studies re-
veal equivalent effects of dexamethasone and topical 
TCL in experimental models of allergy, the need to add 
topical steroids in these cases points to a limitation of 
TCL therapy and the reduced efficacy of TCL for the 
management of the inflammatory process, as compared 
with steroids(28).
The option to not restrict the use of AIs and MCSs 
was based on a previous study of the same group of pa-
tients, which demonstrated neither benefit nor harm 
associated with the co-administration of TCL and olopa-
tadine(29).
The high cost of medication is a limiting factor for 
some patients. Three patients used TCL irregularly and 
discontinued its use because of a lack of economic re-
sources, even though they experienced symptom impro-
vement. Although there has been a reduction in recent 
years, the monthly price of TCL remains about six-fold 
higher than topical dexamethasone 8.50 vs. 1.88 USD, 
respectively(30).
Despite the limitations regarding the sample size and 
study design, the results of this study support the use of 
topical TCL as an effective and safe option for the treatment 
of VKC, with good patient compliance. Further studies 
with longer follow-up periods and larger samples are 
necessary to confirm this hypothesis.
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